Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry
ISSN: 0975-413X
Abstract
Sodium-glucose co-transporter 2 (SGLT2) Inhibitors: New Target for Type 2 Diabetes Mellitus (T2DM) Review
Author(s): Swapna VadlamaniIntroduction: Knocking out type2 diabetes by new insulin independent renal glucose transporters as targets, reducing the side effects related to high rise in glucose levels is a more efficient way to manage diabetes. Sodium-glucose co-transporter 2 (SGLT2) inhibitors block reabsorption of glucose back into the blood and stimulate secretion in urine in a way controlling blood glucose levels.
Areas discussed: We emphasize in this review an overview of type 2 diabetes. New insulin independent targets, SGLT family inhibitors and their mechanism of action are briefly discussed. Molecular modeling studies carried out for new analogues of SGLT2 were indicated and also about current marketed SGLT drugs their safety issues are briefly outlined.
Conclusion: SGLT2 inhibitors are very promising drugs for near future, where insulin sensitization is a problem. A combination of drugs related to insulin dependent pathway and also independent pathway like SGLT2/SGLT1 drugs will be more effective in glycemic control with lesser side effects.
Select your language of interest to view the total content in your interested language
Google Scholar citation report
Citations : 15261
Der Pharma Chemica received 15261 citations as per Google Scholar report
Der Pharma Chemica peer review process verified at publons
